marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2025-Q2
added 07-22-2025
Medpace Holdings Income Statement 2011-2025 | MEDP
Annual Income Statement Medpace Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
10.2 B | 11.1 B | 7.02 B | 6.36 B | 4.73 B | 3.16 B | 2.27 B | 1.47 B | 1.23 B | - | - | - | - | - |
Shares |
31 M | 30.7 M | 32.4 M | 35.9 M | 35.6 M | 35.9 M | 35.5 M | 39.1 M | 35.7 M | - | - | - | - | - |
Historical Prices |
329 | 360 | 217 | 177 | 133 | 85.5 | 64.4 | 36.7 | 34.9 | - | - | - | - | - |
Net Income |
404 M | 283 M | 245 M | 182 M | 145 M | 100 M | 73.2 M | 39.1 M | 13.4 M | -8.67 M | - | 24.8 M | - | - |
Revenue |
2.11 B | 1.89 B | 1.46 B | 1.14 B | 926 M | 861 M | 705 M | 436 M | 422 M | 359 M | - | 273 M | - | - |
Gross Profit |
- | - | - | - | - | 246 M | 216 M | 175 M | 172 M | 156 M | - | 124 M | - | - |
Operating Income |
447 M | 337 M | 279 M | 199 M | 167 M | 127 M | 101 M | 64.9 M | 52.5 M | 20.6 M | - | - | - | - |
Interest Expense |
4.06 M | -655 K | 7.07 M | 3.34 M | 1.18 M | -863 K | 1.06 M | -354 K | -423 K | -1.13 M | - | - | - | - |
EBITDA |
475 M | 361 M | 298 M | 215 M | 179 M | 150 M | 140 M | 111 M | 111 M | 99.4 M | - | 89.4 M | - | - |
Operating Expenses |
- | - | - | - | - | 118 M | 114 M | 110 M | 120 M | 127 M | - | 65.6 M | - | - |
General and Administrative Expenses |
180 M | 161 M | 131 M | 108 M | 92.2 M | 95.2 M | 75.7 M | 63.4 M | 61.5 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Medpace Holdings
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
28.6 M | 30.4 M | 30.6 M | 31 M | 31 M | 30.8 M | 30.8 M | 30.6 M | 30.5 M | 31 M | 31.1 M | 31 M | 32.5 M | 34.9 M | 36 M | 35.8 M | 35.9 M | 35.8 M | 35.5 M | 35.6 M | 35.4 M | 36 M | 36.1 M | 35.9 M | 35.8 M | 35.7 M | 35.7 M | 35.6 M | 35.5 M | 35.5 M | 35.5 M | 38.6 M | 40.2 M | 40.7 M | 40.7 M | 37.1 M | 32.6 M | 32.6 M | 32.6 M | 31.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
90.3 M | 115 M | - | 96.4 M | 88.4 M | 103 M | - | 70.6 M | 61.1 M | 72.9 M | - | 66 M | 49.4 M | 61.3 M | - | 48.6 M | 39.9 M | 43.3 M | - | 41.5 M | 24.1 M | 29 M | 29.8 M | 24 M | 27.5 M | 19.2 M | 22.8 M | 19.3 M | 16.6 M | 14.6 M | 11.3 M | 9.83 M | 9.55 M | 8.45 M | -21 K | 5.04 M | 4.96 M | 3.45 M | -8.58 M | -133 K | 95 K | -59 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
603 M | 559 M | - | 533 M | 528 M | 511 M | - | 492 M | 461 M | 434 M | - | 384 M | 351 M | 331 M | - | 296 M | 278 M | 260 M | - | 230 M | 205 M | 231 M | 230 M | 216 M | 214 M | 201 M | 192 M | 179 M | 170 M | 163 M | 113 M | 111 M | 106 M | 107 M | - | 108 M | 106 M | 99.6 M | - | 92.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
126 M | 114 M | - | 112 M | 105 M | 104 M | - | 84.9 M | 78.4 M | 86.2 M | - | 77.8 M | 60.2 M | 64.2 M | - | 53.7 M | 42.4 M | 47.6 M | - | 46.4 M | 30.1 M | 35.5 M | 36.1 M | 30 M | 35.3 M | 25.9 M | 30.7 M | 26.9 M | 23.3 M | 20.1 M | 15.4 M | 17.2 M | 16.3 M | 15.9 M | 12.9 M | 12.6 M | 14.1 M | 12.9 M | -889 K | 7.2 M | 7.87 M | 6.39 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-2.88 M | -1.82 M | - | -1.02 M | -133 K | 4.59 M | - | -1.6 M | -1.28 M | 687 K | - | 5.65 M | 2.31 M | 1.07 M | - | 1.06 M | 265 K | 924 K | - | 584 K | 239 K | 617 K | - | -273 K | -19 K | -282 K | - | 482 K | 478 K | -153 K | - | -145 K | -125 K | -372 K | - | -378 K | -6 K | -935 K | - | 50 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
133 M | 120 M | - | 119 M | 112 M | 111 M | - | 91.2 M | 84.4 M | 91.6 M | - | 82.8 M | 64.9 M | 68.5 M | - | 57.8 M | 46.4 M | 51.4 M | - | 49.4 M | 32.8 M | 38 M | 36.1 M | 32.1 M | 37.2 M | 27.9 M | 30.7 M | 29.3 M | 25.6 M | 22.4 M | 15.4 M | 19.4 M | 18.4 M | 18.1 M | 12.9 M | 14.5 M | 15.9 M | 14.6 M | -889 K | 8.81 M | 7.87 M | 6.39 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
46.7 M | 57.9 M | - | 49.2 M | 41.5 M | 44.1 M | - | 41.4 M | 39.4 M | 38 M | - | 35.4 M | 33.2 M | 29.4 M | - | 28 M | 27 M | 25.7 M | - | 22.8 M | 21.9 M | 25.1 M | - | 29.1 M | 23.6 M | 21.3 M | - | 18.6 M | 20.5 M | 16 M | - | 16.6 M | 14.8 M | 15.2 M | - | 16.4 M | 14.8 M | 13.5 M | - | 15.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Medpace Holdings (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Danaher Corporation
DHR
|
$ 204.96 | -1.82 % | $ 150 B |  USA |
 |
Centogene N.V.
CNTG
|
$ 0.33 | -6.23 % | $ 30.6 M |  Germany |
 |
Fluidigm Corporation
FLDM
|
$ 3.75 | 1.08 % | $ 308 M | USA |
 |
Global Cord Blood Corporation
CO
|
$ 2.99 | - | $ 399 M |  China |
 |
Oxford Immunotec Global PLC
OXFD
|
$ 21.99 | - | $ 562 M |  Britain |
 |
Genetron Holdings Limited
GTH
|
$ 4.03 | 0.12 % | $ 80.1 M | China |
 |
Lantheus Holdings
LNTH
|
$ 53.55 | 3.3 % | $ 3.71 B | USA |
 |
Chembio Diagnostics
CEMI
|
$ 0.46 | 0.22 % | $ 16.8 M | USA |
 |
Meridian Bioscience
VIVO
|
$ 33.97 | - | $ 1.49 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
$ 0.48 | -20.0 % | $ 1.06 M | USA |
 |
Neogen Corporation
NEOG
|
$ 5.82 | 4.11 % | $ 1.26 B | USA |
 |
Quotient Limited
QTNT
|
$ 0.32 | -11.32 % | $ 1.1 M |  Schweiz |
 |
Pacific Biosciences of California
PACB
|
$ 1.51 | 7.86 % | $ 383 M | USA |
 |
Bioventus
BVS
|
$ 6.76 | 1.65 % | $ 423 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
$ 165.21 | - | $ 10.7 B | USA |
 |
Heska Corporation
HSKA
|
$ 119.99 | - | $ 1.31 B | USA |
 |
Trinity Biotech plc
TRIB
|
$ 1.06 | -0.47 % | $ 61.9 M |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
$ 32.79 | 5.37 % | $ 1.9 B | USA |
 |
Motus GI Holdings
MOTS
|
$ 0.17 | -34.28 % | $ 263 K |  Israel |
 |
Biocept
BIOC
|
$ 0.43 | -13.05 % | $ 7.29 M | USA |
 |
VolitionRx Limited
VNRX
|
$ 0.65 | -0.31 % | $ 62.5 M |  Singapore |
 |
Syneos Health
SYNH
|
$ 42.98 | - | $ 4.46 B | USA |
 |
Invitae Corporation
NVTA
|
$ 0.09 | - | $ 21.2 M | USA |
 |
DermTech
DMTK
|
$ 0.09 | -11.32 % | $ 2.94 M | USA |
|
Akumin
AKU
|
$ 0.29 | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
$ 23.59 | 2.92 % | $ 655 M | USA |
 |
DarioHealth Corp.
DRIO
|
$ 16.37 | 5.27 % | $ 464 M | Israel |
 |
Brainsway Ltd.
BWAY
|
$ 15.53 | 1.94 % | $ 99.4 M | Israel |
 |
PerkinElmer
PKI
|
$ 115.24 | -0.91 % | $ 14.7 B | USA |
 |
OpGen
OPGN
|
$ 1.96 | -16.95 % | $ 1.54 M | USA |
 |
Guardant Health
GH
|
$ 65.32 | 2.96 % | $ 8.02 B | USA |
 |
DexCom
DXCM
|
$ 67.78 | 2.65 % | $ 26.2 B | USA |
 |
Organovo Holdings
ONVO
|
$ 2.12 | -2.3 % | $ 19.4 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 8.82 | -2.17 % | $ 94.9 M | China |
 |
Biomerica
BMRA
|
$ 2.88 | 1.41 % | $ 6.62 M | USA |
 |
Fulgent Genetics
FLGT
|
$ 22.83 | 0.88 % | $ 690 M | USA |
 |
Psychemedics Corporation
PMD
|
$ 2.67 | -1.84 % | $ 15.3 M | USA |
 |
Genetic Technologies Limited
GENE
|
$ 0.77 | - | $ 7.1 B |  Australia |
 |
Myriad Genetics
MYGN
|
$ 7.64 | 1.46 % | $ 692 M | USA |
 |
Renalytix AI plc
RNLX
|
$ 0.21 | 5.66 % | $ 22.7 M | Britain |
 |
CareDx, Inc
CDNA
|
$ 14.79 | 0.82 % | $ 795 M | USA |
 |
IQVIA Holdings
IQV
|
$ 200.6 | -0.13 % | $ 36.4 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 28.25 | 1.51 % | $ 20 B |  Niderland |
|
Biodesix
BDSX
|
$ 7.75 | 6.16 % | $ 1 B | USA |
 |
T2 Biosystems
TTOO
|
$ 0.12 | -39.35 % | $ 313 K | USA |
 |
Quidel Corporation
QDEL
|
$ 27.86 | 0.56 % | $ 1.17 B | USA |
 |
Agilent Technologies
A
|
$ 140.81 | 1.62 % | $ 42.8 B | USA |
 |
Co-Diagnostics
CODX
|
$ 0.39 | 5.12 % | $ 11.4 M | USA |
 |
Celcuity
CELC
|
$ 49.5 | 0.58 % | $ 1.95 B | USA |